Exposure-Response Analysis of Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

被引：0
|
作者：
Agarwal, Suresh [1 ]
Gopalakrishnan, Sathej [1 ]
Mensing, Sven [1 ]
Potluri, Jalaja [1 ]
Hayslip, John [1 ]
Friedel, Anna [1 ]
Menon, Rajeev [1 ]
Salem, Ahmed Hamed [1 ]
机构：
[1] AbbVie Inc, N Chicago, IL USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-116790
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5239
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan
    Asada, Noboru
    Ando, Jun
    Takada, Satoru
    Yoshida, Chikashi
    Usuki, Kensuke
    Shinagawa, Atsushi
    Ishizawa, Kenichi
    Miyamoto, Toshihiro
    Iida, Hiroatsu
    Dobashi, Nobuaki
    Okubo, Sumiko
    Honda, Hideyuki
    Soshin, Tomomi
    Nishimura, Yasuko
    Tsutsui, Atsuko
    Mukai, Harumi
    Yamamoto, Kazuhito
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (07) : 595 - 603
  • [22] Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?
    Pollyea, Daniel A.
    Jordan, Craig T.
    CURRENT OPINION IN HEMATOLOGY, 2019, 26 (02) : 71 - 76
  • [23] Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia
    Liang, Peiqi
    Xie, Yan
    Liu, Ziyi
    Wang, Dong
    Li, Qian
    Lu, Yin
    Xue, Shengli
    Wang, Ying
    Chen, Suning
    Wu, Deipei
    Fu, Jianhong
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1219 - 1226
  • [24] Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
    Jonas, Brian A.
    Wei, Andrew H.
    Recher, Christian
    DiNardo, Courtney D.
    Jang, Jun-Ho
    Pratz, Keith
    Panayiotidis, Panayiotis
    Montesinos, Pau
    Yeh, Su-Peng
    Ivanov, Vladimir
    Fiedler, Walter
    Yamauchi, Takahiro
    Duan, Yinghui
    Mendes, Wellington
    Potluri, Jalaja
    Tews, Bjorn
    Ofran, Yishai
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (08) : E299 - E303
  • [25] Low-Dose IA with Venetoclax Regimen As Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
    Zheng, Weiyan
    BLOOD, 2023, 142
  • [26] Safety and Efficacy of Venetoclax Combined with Hypomethylating Agents or Low-Dose Cytarabine for Acute Myeloid Leukemia before and after Allogeneic Hematopoietic Cell Transplantation
    Pessoa Mendes, Rafael Fernandes
    Fatobene, Giancarlo
    Molla, Vinicius
    Helman, Ricardo
    Rodrigues, Morgani
    Schmidt Filho, Jayr
    Novis, Yana
    Rodrigues, Celso Arrais
    Rocha, Vanderson
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S300 - S300
  • [27] More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine
    Aldoss, Ibrahim
    Marcucci, Guido
    CHINESE CLINICAL ONCOLOGY, 2019, 8
  • [28] Venetoclax and Posaconazole Plus Standard Dose Cytarabine or Azacytidine for Newly Diagnosed Acute Myeloid Leukemia
    Tran-Der Tan
    Chiou, Lun-Wei
    BLOOD, 2020, 136
  • [29] Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
    Amador-Medina, Lauro Fabian
    Crespo-Solis, Erick
    Turrubiates-Herna, Francisco Javier
    Santibanez-Bedolla, Karla Edith
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 : S322 - S331
  • [30] Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis
    Yao Qin
    Pu Kuang
    Ting Liu
    Clinical and Experimental Medicine, 2023, 23 : 219 - 227
12345